Form 4: Globus Medical Director Sells Shares Under 10b5-1 Plan

Globus Medical Director Ann D. Rhoads sold 10,000 shares of Class A Common Stock in pre-planned transactions.

Summary

• Ann D. Rhoads, a Director of Globus Medical Inc. (GMED), reported the sale of 10,000 shares of Class A Common Stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan established on November 8, 2024.
• On November 7, 2025, 8,000 shares were sold at a price of $81.00 per share.
• On November 10, 2025, an additional 2,000 shares were sold at a price of $85.00 per share.
• Following these transactions, Ann D. Rhoads beneficially owns 15,384 shares of Class A Common Stock.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even under a pre-planned 10b5-1 arrangement, can be interpreted with slight caution by investors, though it doesn't necessarily indicate a negative outlook on the company's future.

Negatives

• A director sold a significant number of shares (10,000 shares) of the company's stock.

Risks

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock is fully valued.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the insider selling with slight caution, though the 10b5-1 plan suggests it is not based on new, undisclosed negative information.

Key Dates

Recommendation

The filing reports routine insider selling under a pre-established 10b5-1 plan. While insider sales can sometimes be a yellow flag, the pre-planned nature mitigates immediate concerns about new negative information. This single transaction is unlikely to fundamentally alter the investment thesis for Globus Medical, warranting a 'hold' unless other factors suggest a change.

Keywords

Globus Medical, GMED, Insider Trading, Form 4, Stock Sale, Director, Ann D. Rhoads, 10b5-1 Plan